[
  {
    "ts": null,
    "headline": "Top 10 High-Yield Dividend Stocks For September 2025",
    "summary": "My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns. Check out September's top picks here.",
    "url": "https://finnhub.io/api/news?id=82e27aec9fcdaa5c710e100371b609fa13189598ff225b75dbd2de6739b9a04b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756679728,
      "headline": "Top 10 High-Yield Dividend Stocks For September 2025",
      "id": 136592868,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158691690/image_2158691690.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns. Check out September's top picks here.",
      "url": "https://finnhub.io/api/news?id=82e27aec9fcdaa5c710e100371b609fa13189598ff225b75dbd2de6739b9a04b"
    }
  },
  {
    "ts": null,
    "headline": "NVIDIA Corporation (NVDA): Take A Look At Jim Cramer’s 1,000+ Words About The Stock After Q2 Earnings",
    "summary": "We recently published 11 Latest Stocks That Jim Cramer Just Talked About. NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks Jim Cramer recently discussed. The end of August is seeing some investor jitteriness when it comes to NVIDIA Corporation (NASDAQ:NVDA)’s shares. After the stock failed to close higher following its fiscal Q2 earnings report, the […]",
    "url": "https://finnhub.io/api/news?id=8ca1a09cca04124bbf371defbef9c0670b2281b4f73773d8aace0130bc9b88f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756648707,
      "headline": "NVIDIA Corporation (NVDA): Take A Look At Jim Cramer’s 1,000+ Words About The Stock After Q2 Earnings",
      "id": 136593594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 11 Latest Stocks That Jim Cramer Just Talked About. NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks Jim Cramer recently discussed. The end of August is seeing some investor jitteriness when it comes to NVIDIA Corporation (NASDAQ:NVDA)’s shares. After the stock failed to close higher following its fiscal Q2 earnings report, the […]",
      "url": "https://finnhub.io/api/news?id=8ca1a09cca04124bbf371defbef9c0670b2281b4f73773d8aace0130bc9b88f7"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the top most undervalued low volatility stocks to buy now. On August 27, Merck & Co., Inc. (NYSE:MRK) announced that the first patient was dosed in the HERTHENA-Breast04 phase 3 trial that is evaluating “the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of […]",
    "url": "https://finnhub.io/api/news?id=8aecc8819752f9961816a90b7697fb26b06dbec56a4c732d5825a02680f65a08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756613417,
      "headline": "Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial",
      "id": 136590169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the top most undervalued low volatility stocks to buy now. On August 27, Merck & Co., Inc. (NYSE:MRK) announced that the first patient was dosed in the HERTHENA-Breast04 phase 3 trial that is evaluating “the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of […]",
      "url": "https://finnhub.io/api/news?id=8aecc8819752f9961816a90b7697fb26b06dbec56a4c732d5825a02680f65a08"
    }
  },
  {
    "ts": null,
    "headline": "How Much Would It Take To Earn $100 A Month From Merck Stock",
    "summary": "Merck & Co. (NYSE:MRK) is a leading global biopharmaceutical company that researches, develops, and manufactures innovative medicines and vaccines. It will report its Q3 2025 earnings on Oct. 30. Wall Street analysts expect the company to post EPS of ...",
    "url": "https://finnhub.io/api/news?id=d63ad165914b8d10908c70462212f003a08ad1087341f6cd649699ae03440558",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756609264,
      "headline": "How Much Would It Take To Earn $100 A Month From Merck Stock",
      "id": 136596216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. (NYSE:MRK) is a leading global biopharmaceutical company that researches, develops, and manufactures innovative medicines and vaccines. It will report its Q3 2025 earnings on Oct. 30. Wall Street analysts expect the company to post EPS of ...",
      "url": "https://finnhub.io/api/news?id=d63ad165914b8d10908c70462212f003a08ad1087341f6cd649699ae03440558"
    }
  }
]